Juno Therapeutics Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Juno Therapeutics (JUNO) PT Raised to $60 at Cowen
November 3, 2017 6:02 AM EDTCowen raised its price target on Juno Therapeutics (NASDAQ: JUNO) to $60.00 (from $49.00) while maintaining an Outperform rating.
Analyst Chris Shibutani believes robust efficacy, safety and durability data for JCAR017 in DLBCL from more patients at ASH can further bolster confidence in Junos competitive... More
Juno Therapeutics (JUNO) PT Raised to $64 at Wedbush
November 2, 2017 6:43 AM EDTWedbush analyst David Nierengarten raised his price target on Juno Therapeutics (NASDAQ: JUNO) to $64.00 (from $42.00) while maintaining an Outperform rating after the ASH update shows 6mo response rates with JCAR017 in TRANSCEND at high dose are superior to that achieved with competing CAR-Ts (comparing... More
